CHMP recommends Trulicity (dulaglutide) for treatment of T2D - Eli Lilly
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Trulicity, 0.75 mg and 1.5 mg, solution for injection for the treatment of type 2 diabetes mellitus. The applicant for this medicinal product is Eli Lilly Nederland B.V.
The active substance of Trulicity is dulaglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist generated by fusion of a GLP-1 analogue to a modified human immunoglobulin fragment, resulting in a much prolonged half life. Like native GLP-1, dulaglutide leads to an enhancement of glucose-dependent insulin secretion and a reduction of glucagon release.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins